Examining apixaban vs aspirin in patients with cancer and cryptogenic stroke

Ochsner Well being physicians Dr. Richard Zweifler and Dr. Joseph Tarsia are co-authors on a publish hoc evaluation carried out within the ARCADIA randomized medical trial, evaluating the effectiveness of apixaban versus aspirin in stopping adversarial medical outcomes in sufferers with a historical past of most cancers and cryptogenic stroke. The analysis discovered no vital distinction within the threat of main ischemic and hemorrhagic occasions between these taking apixaban and aspirin. The research was revealed within the JAMA Neurology journal.

The ARCADIA research was a multicenter, double-blind, randomized medical trial carried out between 2017 and 2020. The first final result measure was a composite of main ischemic and hemorrhagic occasions, together with ischemic stroke, systemic embolism, myocardial infarction, or vascular loss of life. A complete of 1,015 contributors have been enrolled within the trial and adopted up for a median period of 11.1 months.

Individuals within the research have been adults with current cryptogenic stroke and biomarker proof of atrial cardiopathy, equivalent to an enlarged left atrium or excessive ranges of natriuretic peptides. Additionally they had a historical past of most cancers inside the previous ten years.

The findings of this publish hoc evaluation recommend that each apixaban and aspirin could also be efficient in stopping adversarial medical outcomes in sufferers with a historical past of most cancers and cryptogenic stroke. Nonetheless, additional research are wanted to substantiate these outcomes and decide the optimum therapy for this affected person inhabitants.

“Our findings from the ARCADIA trial present vital insights into the impression of apixaban and aspirin on sufferers with a historical past of most cancers and cryptogenic stroke. Though we didn’t observe a big distinction within the threat of main ischemic and hemorrhagic occasions, that is solely the start. Shifting ahead, we plan bigger research that can present higher energy to guage potential variations in antithrombotic methods in cryptogenic stroke sufferers with a most cancers historical past,” mentioned Dr. Richard Zwiefler.

Furthermore, it’s important to notice that this publish hoc evaluation was not pre-specified within the authentic research protocol and ought to be interpreted with care.

Offered by
Ochsner Well being System